Robinson James George's Form 4 filing
Nymox Pharmaceutical Corp (NYMXF) · filed May 6, 2022
- Accession no.
- 0001640334-22-000918
- Filed
- May 6, 2022
- Trade date
- May 2, 2022
- Filing delay
- 4 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction and 1 derivative transaction. Open-market purchases total $1.90M. It was filed 4 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Robinson James GeorgeCIK 0001651844 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 2, 2022 | Common Stock | PPurchaseAcquired | +1,151,515 | $1.65 | +$1,899,999.75 | 4,702,065 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 2, 2022 | Common stock | PPurchaseAcquired | +1,151,515 | $0.00 | $0 | 1,151,515 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.